Use of Bortezomib in recurrent and refractory multiple myeloma and impaired renal function

被引：0
|
作者：
Falcone, A. [1 ]
Sanpaolo, G. [1 ]
Bodenizza, C. [1 ]
Carella, A. M. [1 ]
Dell'Olio, M. [1 ]
Mantuano, S. [1 ]
Melillo, L. [1 ]
Merla, E. [1 ]
Scalzulli, F. [1 ]
Cascavilla, N. [1 ]
机构：
[1] IRCCS Casa Sollievo Sofferenza, San Giovanni Rotondo, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：233 / 233
页数：1
相关论文
共 50 条
  • [21] Bortezomib use and outcomes for the treatment of multiple myeloma
    Loke, Crystal
    Mollee, Peter
    McPherson, Ian
    Walpole, Euan
    Yue, Mimi
    Mutsando, Howard
    Wong, Phillip
    Weston, Helen
    Tomlinson, Ross
    Hollingworth, Samantha
    INTERNAL MEDICINE JOURNAL, 2020, 50 (09) : 1059 - 1066
  • [22] Perspective on the current use of bortezomib in multiple myeloma
    San-Miguel, Jesus
    Blade, Joan
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2006, 91 (07): : 871 - 872
  • [23] Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma
    Ning, Yang-Min
    He, Kun
    Dagher, Ramz
    Sridhara, Rajeshwari
    Farrell, Ann T.
    Justice, Robert
    Pazdur, Richard
    ONCOLOGY-NEW YORK, 2007, 21 (12): : 1503 - 1508
  • [24] Pegylated liposomal doxorubicin and bortezomib in relapsed/refractory multiple myeloma
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (07): : 453 - 455
  • [25] Bortezomib asociated to dexamethasone in patients with relapsed/refractory multiple myeloma
    de la O, G. M. Maria
    Garcia-Delgado, R.
    Cuesta, M. A.
    Garrido, P.
    Dominguez, B.
    Hernandez, F.
    Galan, M.
    Sanchez, A.
    Garcia-Sanchez, R.
    Lopez, E.
    Perez, E.
    Bailen, A.
    Heiniger, A. I.
    Ramirez, G.
    Garcia, A.
    Jurado, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 482 - 483
  • [26] ENDEAVOR: carfilzomib superior to bortezomib in relapsed and refractory multiple myeloma
    不详
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2016, 77 (01) : 13 - 13
  • [27] Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma
    Richardson, Paul G.
    Badros, Ashraf Z.
    Jagannath, Sundar
    Tarantolo, Stefano
    Wolf, Jeffrey L.
    Albitar, Maher
    Berman, David
    Messina, Marianne
    Anderson, Kenneth C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 150 (04) : 428 - 437
  • [28] BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    Cerchione, C.
    Pareto, A. E.
    Zacheo, I.
    Di Perna, M.
    Nappi, D.
    Peluso, I.
    Ferrara, K.
    Pane, F.
    Catalano, L.
    HAEMATOLOGICA, 2018, 103 : S116 - S117
  • [29] Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma
    Mele, Giuseppe
    Pinna, Salvatore
    Alloro, Emilia
    Brocca, Maurizio Claudio
    Coppi, Maria Rosaria
    Quarta, Giovanni
    LEUKEMIA RESEARCH, 2007, 31 (05) : 721 - 723
  • [30] Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma
    Berenson, JR
    Jagannath, S
    Barlogie, B
    Siegel, DT
    Alexanian, R
    Richardson, PG
    Irwin, D
    Alsina, M
    Rajkumar, SV
    Srkalovic, G
    Singhal, S
    Limentani, S
    Niesvizky, R
    Esseltine, DL
    Trehu, E
    Schenkein, DP
    Anderson, K
    CANCER, 2005, 104 (10) : 2141 - 2148
12345